Handelsbanken Fonder AB Sells 29,207 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Handelsbanken Fonder AB cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 21.4% during the second quarter, Holdings Channel reports. The institutional investor owned 107,255 shares of the biopharmaceutical company’s stock after selling 29,207 shares during the quarter. Handelsbanken Fonder AB’s holdings in Alnylam Pharmaceuticals were worth $32,287,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ALNY. Assenagon Asset Management S.A. boosted its stake in Alnylam Pharmaceuticals by 20.8% during the second quarter. Assenagon Asset Management S.A. now owns 155,695 shares of the biopharmaceutical company’s stock worth $46,869,000 after acquiring an additional 26,799 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 7.9% during the first quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 65 shares in the last quarter. Glenmede Trust Co. NA increased its stake in shares of Alnylam Pharmaceuticals by 8.3% during the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 56 shares in the last quarter. Groupama Asset Managment lifted its holdings in shares of Alnylam Pharmaceuticals by 2.5% during the first quarter. Groupama Asset Managment now owns 36,767 shares of the biopharmaceutical company’s stock valued at $12,165,000 after purchasing an additional 889 shares during the last quarter. Finally, Segall Bryant & Hamill LLC purchased a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $641,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Up 1.9%

NASDAQ:ALNY opened at $221.20 on Wednesday. The stock has a market cap of $29.60 billion, a price-to-earnings ratio of 41.12 and a beta of 0.30. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The company’s 50 day moving average price is $277.25 and its 200-day moving average price is $303.90. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the topic of several recent research reports. Raymond James Financial upgraded Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target on the stock in a research note on Monday, August 3rd. Barclays lowered their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Weiss Ratings raised Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Citigroup cut their target price on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Finally, Sanford C. Bernstein upgraded Alnylam Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $396.72.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.